TB-500 Fragment 17-23 Preclinical

What It Is

TB-500 Fragment 17-23 is a short acetylated peptide consisting of the seven amino acid residues Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ), corresponding to positions 17 through 23 of thymosin β4 (Tβ4). The N-terminal acetyl group stabilizes the peptide against aminopeptidase degradation. The sequence was identified by structural biology and biochemical mapping as the minimum contiguous sequence in Tβ4 that binds monomeric (G-) actin with significant affinity and mediates the actin-sequestration and cell-migration effects that define the parent molecule's tissue-repair activity.

In the research-peptide lexicon, this fragment is sometimes marketed as "TB-500 Fragment" or "TB-4 Fragment 17-23" — names that are technically misleading because the original "TB-500" code referred to full-length Tβ4 in RegeneRx's development program. The fragment is a distinct chemical entity: it is approximately one-fifth the molecular weight of full-length Tβ4 (~889 Da vs ~4,921 Da), has different pharmacokinetic behavior, and retains only a subset of Tβ4's biological activities. It is not pharmacologically equivalent to full-length TB-500 despite sharing a marketing lineage.

The fragment's existence in the community research-peptide market reflects three practical drivers: shorter sequences are cheaper to synthesize by solid-phase peptide synthesis, higher purity is easier to achieve in a 7-mer than a 43-mer, and the smaller molecular weight permits higher molar doses per milligram of material. The trade-off is biological scope — the fragment captures only the actin-binding function of Tβ4, not the full multi-domain activity. Whether that scope difference translates into a meaningful clinical-benefit difference is not established by controlled human data.

As of April 2026, there are no published randomized controlled trials of TB-500 Fragment 17-23 in humans. The parent molecule Tβ4 (full length) has reached Phase 3 in one topical ophthalmic indication (RGN-259 for neurotrophic keratopathy, Sosne 2023) and Phase 2 in several others; the fragment has not been in any registered clinical trial as a stand-alone agent. All claims about the fragment's human efficacy are therefore extrapolation from Tβ4 full-length data plus preclinical fragment-specific studies.

Mechanism of Action

The fragment's activity is a direct consequence of its structural correspondence to the actin-binding loop of the parent molecule. The non-actin-binding functions of Tβ4 — mediated by other regions of the 43-amino-acid peptide — are not faithfully reproduced by LKKTETQ alone.

• G-actin binding (core mechanism) — LKKTETQ is the minimal contiguous motif responsible for Tβ4's 1:1 binding to monomeric G-actin. The threonine-glutamate-threonine (TET) core and flanking basic residues (LKK) form the contact surface with the actin monomer. The acetylated heptapeptide retains this binding capability with reduced but measurable affinity compared with full-length Tβ4.
• Cell migration via actin polymerization control — By sequestering G-actin locally and releasing it in response to polymerization cues, the fragment supports directional F-actin filament assembly at the leading edge of migrating cells. The functional consequence: accelerated migration of endothelial cells, fibroblasts, and keratinocytes in wound-closure assays.
• Angiogenesis / endothelial tube formation — Philp et al. (FASEB J 2003) demonstrated that LKKTETQ promotes endothelial tube formation in vitro and corneal angiogenesis in vivo. The fragment's angiogenic activity in the endothelial-tube assay is qualitatively similar to full-length Tβ4, though quantitative potency per mole varies across published assay formats.
• Keratinocyte migration and wound closure — Fragment-based wound-healing activity has been demonstrated in rodent dermal wound models, with accelerated epithelialization relative to vehicle controls.
• Hair follicle stem cell effects — Philp et al. (Mech Ageing Dev 2004) showed that the actin-binding site sequence can promote hair-follicle stem cell migration, mirroring an effect established for full-length Tβ4.
• What the fragment does NOT reproduce — The cardiac progenitor cell mobilization documented for full-length Tβ4 (Smart et al. Nature 2007, 2011) maps to additional regions of Tβ4 beyond the actin-binding loop. The full spectrum of anti-inflammatory NF-κB modulation, anti-fibrotic TGF-β modulation, and PINCH-ILK anti-apoptotic signaling may only be partially reproduced by the fragment. Claims that the fragment "is TB-500 minus the other stuff" oversimplify — "the other stuff" is not pharmacologically inert.
• Pharmacokinetics (limited data) — As a short linear peptide without a protective fatty-acid cap or a bulky macromolecular attachment, LKKTETQ is expected to have shorter plasma half-life than full-length Tβ4 (which is ~2–3 days). The acetylation at the N-terminus protects against aminopeptidase cleavage but does not confer a days-long half-life. No formal human PK study has been published.
• No receptor-mediated signaling identified — Like full-length Tβ4, the fragment's activity is mechanistic-physical (actin binding) rather than receptor-agonist. This is unusual among bioactive peptides and explains the broad cell-type responsiveness in vitro.

What the Research Shows

The LKKTETQ research base is modest and almost entirely preclinical. Key publications:

• Philp et al., FASEB J 2003 (PMID 14500546) — Original definitive demonstration that the actin-binding site on Tβ4 promotes angiogenesis. Fragment peptides including LKKTETQ supported endothelial migration, tube formation, and corneal angiogenesis in vivo. Established the "active site" framing for fragment-based Tβ4 therapeutics.
• Sosne et al., FASEB J 2010 (PMID 20179146) — "Biological activities of thymosin β4 defined by active sites in short peptide sequences." Dissected which Tβ4 activities map to which short-peptide substructures. Provided the structural framework for fragment-based therapeutic design. Key finding: LKKTETQ is sufficient for actin-binding-related activities but not for the full spectrum of Tβ4's regenerative biology.
• Philp et al., Mech Ageing Dev 2004 — Thymosin β4 promotes hair-follicle growth. Subsequent fragment work demonstrated that hair-follicle migration signals map to the actin-binding region.
• Goldstein, Hannappel, Sosne, Kleinman (Expert Opin Biol Ther 2012; PMID 22074294) — Review of Tβ4 basic properties and clinical applications, discussing fragment approaches alongside the full-molecule development program.
• Huff et al. (Int J Biochem Cell Biol 2001; PMID 11311852) — β-thymosin family review covering structure-activity relationships of the fragment subsequences.
• Actin-binding structural biology (Safer, Elzinga, Nachmias; J Biol Chem 1991; PMID 1999397) — Identified that Tβ4 is the F-actin-sequestering peptide previously called "Fx." Foundational biochemistry that motivated the fragment program.
• Crockford et al. (Ann N Y Acad Sci 2010; PMID 20536465) — "Thymosin β4: structure, function, and biological properties supporting current and future clinical applications." Addresses both full-length and fragment directions.
• No human trials — PubMed and ClinicalTrials.gov do not list any completed or active registered clinical trial of the isolated Ac-LKKTETQ fragment as a stand-alone therapeutic. All human data relates to the parent molecule (Tβ4 / RGN-259 / RGN-352 / RGN-137).

Human Data

There is no substantive human data for isolated Ac-LKKTETQ. Summary of what exists and what does not:

• Registered clinical trials — none — ClinicalTrials.gov, EU Clinical Trials Register, and UMIN search returns no completed or active trial of the isolated 7-amino-acid fragment as monotherapy.
• Peer-reviewed human case reports or series — none identified — PubMed does not index published human case reports using the fragment as a stand-alone intervention.
• Parent-molecule safety extrapolation — Full-length Tβ4 has accumulated human exposure across dozens of trials (Phase 1–3 for RGN-259 ophthalmic; Phase 1–2 for RGN-352 cardiac IV; Phase 2 for RGN-137 dermal). The aggregate Tβ4 safety signal is favorable. The fragment's safety profile is assumed similar by extrapolation but is not formally characterized.
• Research-chemical community reports — Forum and practitioner observations exist but are uncontrolled, unblinded, and confounded by concurrent BPC-157, GHK-Cu, rehabilitation protocols, and placebo expectation. These are not evidence for efficacy in a scientific sense.
• Gap between preclinical and clinical — The translation from rodent wound-healing / corneal angiogenesis assays (where LKKTETQ is active) to injected systemic human therapy (where pharmacokinetics, distribution, and site-specific activity all matter) has not been validated.

Anyone using the fragment should recognize that the clinical use case is built on a single well-characterized biochemical mechanism plus extrapolation from full-length Tβ4's human data. This is a mechanistic use case, not an evidence-backed clinical use case.

Dosing from the Literature

No dose has been validated in human RCTs. Dosing practices are derived from research-peptide community convention, extrapolation from full-length Tβ4 (TB-500) dosing patterns, and molar-equivalence adjustment for the smaller molecule.

Reconstitution & Storage

TB-500 Fragment 17-23 is supplied in research-peptide channels as lyophilized powder in vials of 2 mg, 5 mg, or 10 mg. Like other short injectable peptides, it requires reconstitution with bacteriostatic water (BAC water) before use.

• Reconstitution — Inject BAC water slowly down the inside wall of the vial at a 45° angle; swirl gently. Do not shake aggressively. Should yield a clear, colorless solution within 30–60 seconds.
• Storage — Lyophilized vials: freezer (−20°C) for long-term storage; refrigerator (2–8°C) acceptable for weeks. Reconstituted solution: refrigerated 2–8°C, use within 21–28 days. Do not freeze reconstituted solution.
• Injection site — Abdomen, thigh, or upper arm SubQ. IM is used by some practitioners for target-tissue proximity, though there is no PK basis for expecting differential effect by injection site.
• Needle — 29G–31G half-inch insulin syringe. Volumes are small; insulin syringes are precise enough for 20–75 unit measurements.
• Inspection — Discard if cloudy, discolored, or showing visible particulate. Short peptides are generally stable; contamination of BAC water is the most common failure mode.
• Purity considerations — Seven-residue peptides are generally easy to synthesize to high purity (>98% by HPLC). Independent third-party Certificate of Analysis (HPLC + mass spec) is the practical floor for due diligence. Truncation and deletion sequences are the most common impurity in cheap research-grade product.

→ Use the Kalios Dosing Calculator for exact syringe units

Side Effects & Risks

No formal human safety database exists for TB-500 Fragment 17-23. Risks are extrapolated from full-length Tβ4 experience plus general injectable-peptide considerations.

• Injection-site reactions — Mild erythema, tenderness, and bruising are typical for any SubQ peptide. Usually self-limited within 24–48 hours.
• Fatigue / flu-like malaise — Anecdotal reports early in dosing, similar to full-length TB-500 community reports. Not characterized in controlled studies.
• Head pressure / sinus congestion — Occasional community reports within hours of dosing.
• Angiogenic / proliferative theoretical concerns — Because the fragment retains pro-angiogenic and pro-migratory activity, a theoretical concern about accelerating growth in pre-existing malignancies applies by extrapolation from full-length Tβ4. Active malignancy is a rational contraindication by analogy to the parent molecule's trial exclusion criteria.
• Hypersensitivity — Possible as with any injectable peptide; discontinue if urticaria, rash, or other hypersensitivity signs appear.
• Drug interactions — Largely unstudied. Theoretical interactions with anti-angiogenic cancer therapies (mechanistically opposed to the fragment's action) and with chronic high-dose corticosteroids (blunt repair signaling) apply by extrapolation.
• WADA — Thymosin β4 and derivatives have been prohibited under Section S2 (peptide hormones, growth factors, related substances and mimetics) since 2011. The fragment, as a Tβ4-derived peptide, plausibly falls under the same prohibition; athletes subject to anti-doping testing should consult their federation.
• Purity risk — Because the fragment is often marketed as a cheaper alternative to full-length TB-500, some suppliers reduce purity-control costs. Lot-to-lot variability in impurity profile is a practical risk.
• No characterized long-term safety — Zero years of controlled human exposure data on the isolated fragment. Anyone considering chronic use should acknowledge this evidence gap.
• Pregnancy and lactation — Contraindicated. No reproductive safety data.
• Pediatric use — Contraindicated. No pediatric safety or efficacy data.

Bloodwork & Monitoring

No formal monitoring protocol exists. Reasonable research-context awareness:

• Baseline CMP and CBC — Liver function, renal function, hematology. Repeat at 8–12 weeks during extended cycles.
• Inflammatory markers — hsCRP / ESR at baseline for context in chronic inflammatory / soft-tissue use cases.
• Target-tissue imaging — For MSK applications, baseline MRI or ultrasound of the target tissue is the objective way to characterize structural change versus subjective pain reports.
• Cancer screening — Age-appropriate screening (colonoscopy, mammography, PSA, dermatologic exam) before prolonged cycles. A rational precaution given the fragment's pro-migratory and pro-angiogenic mechanism.
• Injection-site photo log — Useful for tracking local reactions across weeks.
• Symptom diary — Subjective pain, range of motion, and functional markers across the cycle help distinguish real response from placebo.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Supportive Nutrition & Context

If the fragment is used for tissue-repair goals, the structural and metabolic inputs for repair dominate the outcome. These are the same inputs that matter for any tissue-repair protocol:

• Protein (1.6–2.2 g/kg/day) — Non-negotiable for repair. Distribute across 3–5 feedings. Leucine-rich sources (whey, eggs, lean meat) drive mTOR-mediated protein synthesis.
• Collagen peptides + vitamin C — 15 g hydrolyzed collagen + 50 mg vitamin C ~1 hour before rehab/loading sessions (Shaw 2017). Supplies substrate during the collagen-synthesis window. Applies to tendon, ligament, and connective-tissue goals.
• Vitamin D (2,000–5,000 IU to serum 40–60 ng/mL) — Deficiency impairs bone and tendon repair independent of any peptide.
• Zinc (15–25 mg) — Cofactor for collagen cross-linking and matrix metalloproteinase regulation. Avoid chronic >40 mg (copper depletion risk).
• Magnesium (300–400 mg) — Broad cofactor for ATP generation and protein synthesis.
• Omega-3 (2–3 g EPA/DHA) — Resolves inflammation without blunting it; preferred over chronic NSAIDs during early tissue repair.
• Creatine monohydrate (3–5 g) — Supports training load during rehabilitation. Emerging data on tendon benefits.
• Glycine (3–5 g at night) — Rate-limiting amino acid for collagen synthesis, often underconsumed in muscle-meat-dominant diets.
• Progressive mechanical loading — The single highest-leverage intervention. Tissue remodeling is driven by applied stress; without structured rehab or training load, peptide support has nothing to remodel toward.
• Things to avoid — Chronic alcohol (impairs tendon healing), smoking/nicotine (vasoconstrictive; strongly antagonizes repair), chronic NSAIDs during early inflammatory phase (impairs organized collagen deposition in animal models), and intra-tendon corticosteroid injections (directly antagonize repair signaling).

What to Expect — Timeline

The following reflects community-reported patterns for the fragment, extrapolated from the longer community experience with full-length TB-500. Individual response varies substantially; the evidence base is not controlled.

• Week 1 (loading) — Users typically describe minimal subjective change. Occasional mild fatigue for 24–48 hours after the first few doses. Half-life of the fragment is shorter than full-length Tβ4; cumulative effects are less pronounced.
• Week 2–4 — Earliest subjective reports of reduced chronic inflammation or improved post-exertion recovery in responders. Highly variable.
• Week 4–8 — Typical response window for MSK applications in community reports. Users targeting tendinopathy or chronic soft-tissue injury often report their first clearer signal here if a signal is going to emerge.
• Week 6–8 (end of loading) — Practical endpoint of a loading cycle. Loading dose transitions to maintenance or cessation.
• Post-cycle (weeks 1–4 off) — Fragment plasma clearance within hours to days. If benefit persists, it reflects tissue remodeling rather than ongoing drug action.
• Non-responders — Estimated a significant fraction of community users report no benefit. Common reasons: product quality, concurrent conditions that structurally require intervention beyond peptide support, absence of mechanical loading / rehabilitation component, or misattribution of benefit that would have occurred with time alone.
• Red flags to stop — Persistent fatigue past week 2, new-onset unexplained headache, any new lumps or skin changes, persistent fever. Stop first, evaluate second.

Regulatory Status

Related Compounds

People researching TB-500 Fragment 17-23 often also look at these:

Next Steps

Key References

1. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID: 14500546. (Foundational: defines LKKTETQ as sufficient for angiogenic and migratory activity.)
2. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PMID: 20179146. (Defines which Tβ4 activities map to which short sequences.)
3. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037010.
4. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PMID: 11311852.
5. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID: 1999397.
6. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-1166. PMID: 6940133. (Parent molecule discovery.)
7. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID: 20536465.
8. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294.
9. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145. (Cardiac progenitor activity — not reproduced by fragment.)
10. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969.
11. Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-5117. PMID: 26241398.
12. Sosne G, Kim C, Kleinman HK. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023;24(1):554. (Full-length parent molecule Phase 3.)
13. WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. Thymosin β4 and derivatives prohibited since 2011.
14. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) under Section 503A / 503B. FDA.gov. Updated 2025.
15. Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis. Am J Clin Nutr. 2017;105(1):136-143. PMID: 27852613. (Substrate-side adjunct reference.)